GlassScriptPhysician profile
Thomas D Gurley
NPI 1326224635
$8,682.26
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $2,449 · 2021: $2,619 · 2022: $1,710 · 2023: $13.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,257.78 | 2019-2022 | |
| Viiv Healthcare Company | $1,103.16 | 2019-2022 | |
| Merz North America, INC. | $638.76 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $467.08 | 2019-2022 | |
| Novo Nordisk INC | $443.65 | 2019-2022 | |
| Janssen Biotech, INC. | $421.22 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $382.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.70 | 2019-2022 | |
| Lilly USA, LLC | $327.09 | 2020-2022 | |
| Theratechnologies INC. | $322.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $307.04 | 2019-2022 | |
| Allergan, INC. | $236.75 | 2019-2020 | |
| Napo Pharmaceuticals INC | $203.54 | 2020-2022 | |
| Abbvie INC. | $189.89 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $186.20 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.